Oncotelic Therapeutics Advances Oncology and Drug Delivery Efforts
Biotechnology firm Oncotelic Therapeutics is focusing on nanotechnology-enabled drug delivery and AI. The company has reported progress in both its drug development pipeline and financial filings.
Oncotelic Therapeutics Inc., a clinical-stage biotechnology company, is advancing its work in oncology and drug delivery through the application of nanotechnology and artificial intelligence.
The company, trading on OTCQB under the ticker OTLC, has issued several updates in May 2026. These include developments related to its Deciparticle™ nanomedicine platform and AI-driven oncology research. CEO Vuong Trieu presented the company's platform at the BIO International Convention 2026.
In mid-May, Oncotelic Therapeutics filed its first quarter 2026 financial results. The company's focus remains on oncology, AI-assisted drug development, and advanced drug delivery systems.
Additionally, Sapu Nano, an affiliate, announced the first patient dosing in a Phase 1b clinical trial for Sapu003, an intravenous formulation of everolimus using the Deciparticle™ technology. This trial is evaluating weekly IV Sapu003 in patients with advanced mTOR-sensitive solid tumors, including various cancers like breast and kidney cancer.